SYMJEPI Products Now Available in the WalgreensSYMJEPI Products Now Available in the Walgreens Prescription Savings Club, with the Lowest Prices for Epinephrine Products
ADMP) today announced that its SYMJEPI® (epinephrine) Injection products are now available to members of the Walgreens Prescription Savings Club program, for a discounted price of $99.99 for a two-pack, the lowest price offered for epinephrine products through the Walgreens Prescriptions Savings Club, and the lowest price for epinephrine devices on the market1.
finance.yahoo.com
Stockstotrade
Express, Inc. Announces $140 Million in Additional FinancingExpress, Inc. Announces $140 Million in Additional Financing to Bolster Liquidity
EXPR today announced that it has entered into a definitive loan agreement with Sycamore Partners as lead lender, along with Wells Fargo and Bank of America Merrill Lynch, that strengthens its liquidity position by an additional $140 million.
The new financing includes a $90 million FILO Term Loan with a maturity date of May 24, 2024, and a $50 million Delayed Draw Term Loan, to be repaid upon receipt of a CARES Act tax refund expected to be received in the second quarter of 2021.
This financing is in addition to the Company’s existing $250 million asset-based loan facility, of which it had previously drawn $165 million.
finance.yahoo.com
A 1 bill Val a 9$ price targetTwitter hyping: A 1 bill Val a 9$ price target by ARGUS research
twitter.com
GME Record Surge Gives Win to Reddit Army in Citron ClashGameStop Record Surge Gives Win to Reddit Army in Citron Clash
In the battle between short-seller Citron Research and an army of Reddit-charged day traders, GameStop Corp.’s seemingly endless rally to an all-time high has given the stock’s bulls a win, though not without controversy.
GameStop’s 75% gain through Friday comes after it more than doubled the week before and marks the most volatile 10-day period on record, data compiled by Bloomberg show. The stock was halted at least four times in New York as it surged as much as 79% to $76.76 as Reddit users ran wild. It was last 44% higher after trading resumed.
At one point, the video-game retailer was the most actively traded U.S. company with a market value above $200 million, data compiled by Bloomberg show, as millions of shares exchanged hands every few minutes.
GameStop representatives didn’t return an email seeking comment.
Reddit users continued to pump up their bets with one user saying they relied on it to pay their student loans.
GameStop’s parabolic rise, which has come amid steady and elevated short interest and increasing volume, has showcased the divide between retail bulls and bears betting on a quick return to reality.
GameStop became a “cult stock because of Ryan Cohen’s success with Chewy” and retail investors “appear confident that he can implement omnichannel initiatives that will materially grow their earnings,” Wedbush analyst Michael Pachter said in an email.
For the company to be worth $50 a share it would have to quickly double their growth, Pachter, who has a $16 price target which is the second highest among analyst tracked by Bloomberg, continued. In order to give GameStop credit for higher earnings power, Pachter, who rates the stock at neutral, wants to see Cohen’s strategy.
A backlash against Citron by some vocal Reddit users over its views on GameStop came to a head on Friday when the short seller said it will stop commenting on the stock following the actions of “an angry mob.”
“We are investors who put safety and family first and when we believe this has been compromised, it is our duty to walk away from a stock,” Citron managing partner Andrew Left wrote in a Friday letter.
The statement came a day after Left said in a YouTube video that he’d “never seen such an exchange of ideas of people so angry about someone joining the other side of a trade,” referring in part to Reddit users who have been particularly vocal on the social media site in seeking to promote their positive opinions on the video-game retailer’s stock.
GameStop fans clashed with Citron after the short seller critiqued shares in a tweet on Tuesday and made plans for a Twitter Inc. livestream the following day. The event was initially pushed back for the inauguration of President Joe Biden and then again on Thursday due to attempts to hack the short-seller’s Twitter account.
credited the bulk of last week’s gains to a short squeeze after activist investor and Chewy Inc. co-founder Ryan Cohen was added to GameStop’s board.
Bearish bets have remained steady with 140% of available GameStop shares currently sold short, according to data compiled by S3 Partners. Bears have seen more than $1.74 billion mark-to-market losses this year, according to the financial analytics firm.
“While older existing shorts have been covering some of their positions due to a profit-loss based short squeeze, there is a queue of new short sellers wanting to get short exposure in GME after its recent run-up,” Ihor Dusaniwsky, S3’s managing director of predictive analytics, said by email.
AzurRx BioPharma Announces First Two Patients DosedAzurRx BioPharma Announces First Two Patients Dosed in Phase 2b OPTION 2 Extension Study of MS1819 in Cystic Fibrosis Patients
Due to enrollment in the initial crossover trial being ahead of schedule, we are given an opportunity to thoroughly explore optimal doses and capsule types that will help guide our future development plans for MS1819 in a Phase 3 program. In the meantime, we will continue our preparation for a successful FDA meeting later this year.”
Topline data results for this study are anticipated in Q1 2021, as enrollment remains strong.
finance.yahoo.com
EVgo to Publicly List through CLII spac companyEVgo, an LS Power Company, and Leader in U.S. Electric Vehicle Fast Charging, to Publicly List through Business Combination with Climate Change Crisis Real Impact I Acquisition Corporation
Anticipated net proceeds of approximately $575 million will be used to fully fund and accelerate EVgo’s growth strategy and network buildout. This includes a $400 million fully committed private placement of common stock in EVgo (the “PIPE”). The PIPE is anchored by institutional investors including private funds affiliated with Pacific Investment Management Company LLC (PIMCO), funds and accounts managed by BlackRock, Wellington Management, Neuberger Berman Funds and Van Eck Associates Corporation.
CRIS is co-sponsored by private funds affiliated with PIMCO, which has more than $640 billion in sustainability investments across its portfolios.
Commercial relationships with large automotive OEMs (including General Motors, Nissan and Tesla), rideshare operators (including Lyft and Uber), and major property owners for its host sites (including Albertsons, Wawa, and Kroger), underscore EVgo’s market-leading position in the rapidly growing fast charging market.
LS Power, a leading investment firm focused on power, energy infrastructure and energy innovation, along with EVgo management, who together own 100% of EVgo today, will be rolling 100% of their equity in the transaction and are expected to own approximately 74% of the company upon transaction close.
Pro forma implied equity value of the combined company of $2.6 billion. The transaction is expected to close in the second quarter of 2021, subject to customary closing conditions.
With more than 800 locations in 67 major metropolitan markets across 34 states, EVgo’s network serves a rapidly expanding customer base that currently exceeds 220,000 customers.
a strategic relationship with General Motors, which selected EVgo for a nationwide EV charging infrastructure buildout, whereby EVgo expects to add more than 2,700 additional fast chargers to its network over the next 5 years.
Corporate partners also include Uber and Lyft, which selected EVgo as one of their first charging providers.
EVgo has also worked with Tesla, to enable native fast charging on EVgo’s network.
www.businesswire.com
Termination of a Material Definitive AgreementInvestors appear to be responding to the company filing an 8-K today, which seems to indicate that there will be no dilution. This news went viral on a number of stock trading forums including StockTwits.
Termination of a Material Definitive Agreement.
On January 20, 2021, the Company delivered notice to Lincoln Park Capital Fund, LLC, an Illinois limited liability company (“Lincoln Park Capital”) terminating the Purchase Agreement, dated September 8, 2020 (the “2020 Purchase Agreement”), with Lincoln Park Capital effective January 21, 2021 (the “Termination Date”). The 2020 Purchase Agreement provided that, upon the terms and subject to the conditions and limitations set forth therein, the Company has the right to sell to Lincoln Park Capital up to $26 million of shares of the Company’s common stock, par value $0.01 per share (“Common Stock”), over the 36-month term of the 2020 Purchase Agreement. In consideration for entering into the 2020 Purchase Agreement, the Company issued to Lincoln Park Capital 437,828 shares of the Company’s Common Stock.
sec.report
pulse2.com
BBIG and ZASH Signing of Agreement to Complete Plan of mergerVinco Ventures (BBIG) and ZASH Announce Signing of Agreement to Complete Plan of Merger
Today announced the signing of an Agreement to Complete a Plan of Merger subject to certain conditions, creating exciting acceleration and growth in live-streaming content, video-sharing, distribution and production within its own ecosystem.
At the forefront of today’s digital wave, the Company aims to invest, acquire and merge the best-in-class media, entertainment and content-focused technology companies globally – from East to West – aiming to build a “Virtual Hollywood”, the future of media.
“The Company’s proprietary Influencer Platform has led to over 2 billion video views. With a current follower network of over 350+ million, we are poised to revolutionize the next generation of video distribution,” said Brian McFadden, Chief Strategy Officer.
Vinco’s Chief Strategy Officer, commented, “The merger with ZASH and the resulting combined entity provides current and prospective business partners with the assurance of our ability to scale our production and creative services to meet their growing content creation and distribution needs. The synergies between the two entities will bring immediate scale to the existing business along with clearly identified and obtainable growth initiatives. We are excited to merge with ZASH in our ever-evolving pursuit to ‘Be BIG’.”
www.streetinsider.com
VANGUARD just invested with 2.6 mil sharesInuvo Prices $8.0 Million Common Stock Offering
has entered into a securities purchase agreement with institutional investors for the purchase and sale of 13,333,334 shares of its common stock, par value $0.001 per share, at a price of $0.60 per share, pursuant to a registered direct offering. The gross proceeds of the offering are expected to be $8.0 million before deducting fees and other estimated offering expenses. The closing of the registered direct offering is expected to take place on or about January 19, 2021, subject to the satisfaction of customary closing conditions.
finance.yahoo.com
GigCapital2 Has Entered Into Business Combination AgreementsGigCapital2 Has Entered Into Business Combination Agreements With UpHealth and Cloudbreak to Form Combined Company to List on the NYSE, Creating a Unified and Profitable Global Digital Health Company
In 2021, UpHealth is expected to generate over $190M in revenue and $24M in EBITDA; 69% of the 2021 incremental revenue growth is already contracted.
UpHealth will be positioned for predictable growth and profitability enabling substantial reinvestment opportunities.
Pro forma enterprise value is approximately $1.35 billion.
UpHealth will be a leading global digital healthcare company serving an entire spectrum of healthcare needs and will be established in fast growing sectors of the digital health industry.
The Global Telehealth Platform will consist of a U.S. division and an international division that, together, are anticipated to grow revenues by an additional $47 million in 2021.
The U.S. division of Global Telehealth following the combination, Cloudbreak, is a leading unified telemedicine platform performing more than 100,000 encounters per month on over 14,000 video endpoints at over 1,800 healthcare venues nationwide.
Digital Pharmacy - MedQuest Pharmacy ("MedQuest") is a leading full-service manufactured and compounded pharmacy licensed in all 50 states that pre-packages and ships medications direct to patients. MedQuest serves an established network of 13,000 providers.
UpHealth will have agreements to deliver digital healthcare in more than 10 countries globally. These various companies are expected to generate approximately $115 million in revenue and over $13 million of EBITDA in 2020 and following the combination, UpHealth expects to generate over $190 million in revenue and $24 million in EBITDA in 2021.
The proposed business combinations are expected to be completed in Q1 2021
finance.yahoo.com
Twitter looking to resume the uptrendIn my previous post, I've mentioned that there is a correction coming for Twitter and that was catalyzed after the social platform banned Trump's account.
Price has landed perfectly on the uptrend major support and formed yesterday a nicely looking pinbar.
RIS has turned from oversold zone and if you are more aggressive current price is tempting enough to enter long. I would wait for the additional confirmation from MACD. My long-term target is $58 if bullish conditions are confirmed.
Keep eyes on Boeing - a lot of room for a promising recoveryIt took some time for Boeing to break out of its bullish wedge, but the support held well, and we see some more stubborn attempts from buyers to push the price up.
RSI is rising above 50, MACD has crossed over and the histogram is moving slowly towards positive territory. Earnings are after 7 days. so keep that in mind. An impulse above $216 will confirm the continuation of the bullish trend. My long term target is $250.
What's in for Bank of America after the earnings report?Today we saw the earnings report for Bank of America and it did not meet the investor's expectations. So far the earnings season (for the banks) starts a bit off. The EPS came above expectations at 0.59 versus 0.54 expected. Revenue though came in with a miss - 20.1B against 20.56B expected. The main cause for the miss cited is the COVID-19 pandemic.
RSI is already crossing from overbought territory, though MACD's crossing is lagging. The histogram is showing a divergence with the price which is in line with RSI's early divergence with the price.
My expectations are for a drop towards the trend line support at the $31.35 zone. A breach there may lead to a potential drop towards $30.61 and by this jeopardizing the uptrend.
Tilman Fertitta Is in Talks to List Casino, Dining firm Via FSTTilman Fertitta Is in Talks to List Casino, Dining Assets Via SPAC
Texas billionaire and Houston Rockets owner Tilman Fertitta is in talks to take his casino and restaurant empire public through a merger with blank-check firm Fast Acquisition Corp., according to people with knowledge of the matter.
The special purpose acquisition company is in talks to raise more than $1 billion in new equity to support a transaction, said the people, who asked to not be identified because the matter isn’t public. The deal could value the combined entity at up to $7 billion including debt, one of the people added.
The new company, which Fertitta would still control, is set to include casinos and restaurants under the Golden Nugget and Landry’s umbrellas, they said. If talks are successful, a deal could be announced n the coming weeks. Terms may change and discussions could still fall apart.
Representatives for Golden Nugget and Fast Acquisition declined to comment.
finance.yahoo.com
Oppenheimer Analyst Says buy, following of some positive dataOppenheimer 5-star Analyst Says BioNano Genomics is ready to Execute in 2021.
the latest move was decidedly upbeat. In Wednesday’s session, the stock took off to the tune of 40% following the publication of some positive data.
article which made side-by-side comparisons between Bionano’s optical genome mapping platform Saphyr and PacBio's HiFi chemistry revealed that Saphyr had the upper hand on several metrics.
Across 32 different human genomes, PacBio technologies found only 72% of the large SVs (structural variants) that Bionano’s optical genome mapping (OGM) detected.
Saphyr was also found to be better at locating indels in regions correlated to neurodevelopment.
Additionally, Saphyr appears to be more cost effective. The platform’s estimated cost of $500 per genome coming in far below the $10,000-20,000 per genome when HiFi and SMRT sequencing are put into action.
Oppenheimer’s Kevin DeGeeter believes the data should help Saphyr make further inroads in the “large SV research market.” The analyst views 2021 “largely as an execution year.”
We expect the data to support broader adoption of Saphyr for de novo sequencing and research applications. the 5-star analyst said.
“Furthermore, we expect 2021 to be an important year for adoption of Saphyr for clinical cytogenetics market based on a series of positive recent publications... Based on our current assessment of the competitive landscape, we do not believe long-read sequencing technologies can replicate Saphyr's performance and cost structure for digital cytogenetics testing.”
Accordingly, DeGeeter reiterated an Outperform (i.e. Buy) on BNGO shares, along with a $1.5 price target. The implication for investors? Strong upside of 113% .
Two other analysts have thrown the hat in with a BNGO review recently, one saying Buy and the other recommending a Hold -- all add up to a Moderate Buy consensus rating. Meanwhile, the average price target stands at $1.42, implying gains of 101% could be in the cards over the next 12 months.
finance.yahoo.com
FDA identifies "Assay Kit" able to detect SARS-CoV-2 mutationsU.S. FDA Lists Applied DNA’s Linea™ COVID-19 Assay Kit as 1 of Only 2 EUA-Authorized Tests Able to Detect S-Gene Mutation Found in SARS-CoV-2 U.K. Variant (B.1.1.7)
(FDA) published a safety communication (the "Communication") that identifies the Company’s Linea™ COVID-19 Assay Kit (the "Assay Kit") as one of only two tests marketed under the FDA’s Emergency Use Authorization (EUA) that are potentially able to identify certain SARS-CoV-2 mutations, including a mutation found in the U.K. variant of SARS-CoV-2 (B.1.1.7). According to recent publications, the B.1.1.7 variant has been identified within the United States and may be associated with an increased risk of transmission of the virus that causes COVID-19.
Based on analysis conducted by the Company and FDA, one of the two S-gene targets (S1 and S2) of the Assay Kit has significantly reduced sensitivity in the presence of certain S-gene mutations, including a mutation found in the B.1.1.7 variant.
finance.yahoo.com
Disney's price on a crossroadHolidays are over and it is time to get back into the markets, refreshed and with new strength.
I am making another revision of Disney as the price on Friday closed at the internal trend support and played out the small bearish flag. Volumes were higher than Thursday as there were 12.23M shares traded against 8.951M shares on the day before Friday. The activity had increased before the weekends, but with that dip buying before the close, it looked more like long position covering.
Now two options are on the table that will be crucial if confirmed by the price action.
1. Price dips inside the $165 - $169 zone and we may see potential trend-reversing price action;
2. The zone holds and Disney'sprice resumes inside the uptrend with the broader market;
Be cautious on the first trading day after the break.
Hormel Foods Corp. $HRL - investment idea 💡 This idea is based on my technical analysis only.
Do your research and trade on your own risk!
AEye Said in Talks to Go Public Via Cantor Blank-Check FirmAEye Said in Talks to Go Public Via Cantor Blank-Check Firm
CF Finance Acquisition Corp. III raised $230 million in IPO
Artificial-perception startup AEye Inc. is in talks to go public through a merger with CF Finance Acquisition Corp. III, a Cantor Fitzgerald LP blank-check firm, according to people with knowledge of the matter.
The valuation couldn’t immediately be learned. A deal hasn’t been finalized, and terms could change or talks could collapse. Shares of CF Finance Acquisition Corp. III jumped as much as 32% after Bloomberg reported the discussions.
A Cantor Fitzgerald representative declined to comment. AEye didn’t immediately respond to requests for comment.
California-based AEye makes sensor technology, known as lidar, for use in autonomous vehicles. Continental AG, Europe’s second-largest car-parts supplier, acquired a minority stake in AEye in October. Other investors include Kleiner Perkins, LG Electronics, Intel Capital and Airbus Ventures, according to AEye’s website.
CF Finance Acquisition Corp. III, led by CEO Howard Lutnick and President Anshu Jain, raised $230 million in a November initial public offering, with a goal of striking a deal in any industry or geography. “The company intends to focus on industries where its management team and founders have experience , including the financial services, health care, real estate services, technology and software industries,” it said at the time.
An earlier Cantor blank-check firm last year agreed to merge with GCM Grosvenor Inc. in a deal that took the investment manager public. In November, CF Finance Acquisition Corp. II reached a deal with View Inc., a maker of smart windows that use artificial intelligence. In December, Cantor raised $500 million for its fourth special purpose acquisition company, and this month filed for a fifth SPAC.
www.bloomberg.com
Owl Rock, Dyal Capital to go public via SPAC mergerOwl Rock and Dyal to combine to form Blue Owl, a differentiated alternative asset manager with industry leading Direct Lending and GP Capital Solutions businesses
Combined firm to manage over $45.0 billion in assets
Blue Owl to become publicly listed through a business combination with Altimar, a SPAC sponsored by an affiliate of HPS Investment Partners (NYSE:ATAC)
Blue Owl is expected to be listed on the NYSE under the ticker symbol "OWL" following the expected close of the transaction in the first half of 2021.
Transaction expected to provide approximately $1.8 billion in gross proceeds, comprised of Altimar’s $275 million of cash held in trust (assuming no redemptions) and a $1.5 billion fully committed, oversubscribed, common stock PIPE at $10.00 per share, including investments from ICONIQ Capital, CH Investment Partners, Koch Companies Defined Benefit Master Trust, the Federated Hermes Kaufmann Funds, and Liberty Mutual Investments
The founders and senior managers of Blue Owl will retain their equity stakes through the combined entity’s transition into a publicly listed company, promoting continued alignment.
The combined entity is expected to have a post-transaction market capitalization of approximately $12.5 billion.
finance.yahoo.com
SSRM Technical Analysis 🧙SSR Mining Inc is a minerals company focused on mining precious metals in the Americas. More than half Silver Standard's revenue is attributable to the production of gold, with a significant portion derived from silver production. The company owns and operates the Marigold mine in Nevada, United States; the Seabee Gold Operation in Saskatchewan, Canada; and the Pirquitas mine in Argentina. The majority of gold production is derived from the Marigold mine, and Silver Standard's silver production is principally derived from the Pirquitas mine.
If you understand the idea,🎯 press a thumb up! 👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!
Achronix to List on Nasdaq Through Merger With ACE ConvergenceAchronix is the only independent supplier of high-performance FPGAs and eFPGA IP based data acceleration solutions used in high-growth applications including AI, cloud computing, 5G, networking and automotive driver assistance
Highly differentiated financial profile with estimated 2020 revenues of approximately $105 million, 79% gross margins and 35% operating margins with migration to next-generation products driving an estimated revenue CAGR of 20% to 25% from 2020 to 2025
Business combination with ACE Convergence Acquisition Corp. (Nasdaq: ACEV) positions Achronix to capitalize on non-cancellable backlog in excess of $160 million and over $1.1 billion in identified pipeline opportunities driven by Speedster® and Speedcore™ products
Approximately $2.1 billion estimated post-transaction equity value based on current assumptions with up to $330 million in gross cash proceeds to the company, assuming minimal redemptions
Oversubscribed $150 million fully committed common stock concurrent PIPE financing at $10.00 per share anchored by ACE Equity Partners LLC, funds and accounts managed by BlackRock and Hedosophia; and with participation from other institutional investors
Achronix expected to be listed on Nasdaq under the ticker symbol "ACHX" following an anticipated transaction close by the end of the first half of 2021
Customer validation of Achronix’s products is substantiated by nearly $240 million in orders received in 2020 . Achronix’s new Speedster7t and Speedcore products, built on leading-edge process technology, have contributed to a design pipeline value in excess of $1.1 billion and are expected to drive Achronix’s future growth.
"The next era of growth and opportunity is in the trillions of connected devices providing compute-intensive intelligence, all fueled by network connectivity and 5G,"
finance.yahoo.com
DBV Technologies rally on Positive FDA CommunicationDBV Technologies Spikes on Positive FDA Communication
DBV Technologies received positive responses from the U.S. Food and Drug Administration regarding its application for a peanut allergy treatment.
The U.S. FDA provided type A meeting requests to the questions the French company submitted in October following its receipt of a complete response letter in connection with its biologics license application (BLA) for Viaskin Peanut DBV712, its once-daily epicutaneous patch to treat peanut allergy in children ages four to 11.
"We are very encouraged by the positive feedback received from the FDA, and we appreciate the clarity provided," said Daniel Tassé, CEO of DBV Technologies. “We look forward to working with our investigators, clinical trial sites, and key stakeholders as we continue in our development of investigational Viaskin Peanut."
DBV says it will address details about a new human factor validation study and additional chemistry, manufacturing and controls data in subsequent communication with the FDA.
"We intend to advance a remediation plan for Viaskin Peanut and work closely with FDA to review protocols and re-file our BLA as soon as possible, so that we can bring Viaskin Peanut, if approved, to patients suffering from peanut allergies," Tassé said.
www.thestreet.com
finance.yahoo.com
